A237690 Stock Overview
Provides custom manufacturing services for active pharmaceutical ingredient and intermediates in South Korea and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 4/6 |
| Past Performance | 5/6 |
| Financial Health | 5/6 |
| Dividends | 1/6 |
Rewards
Risk Analysis
No risks detected for A237690 from our risk checks.
My Notes
Capture your thoughts, links and company narrative
ST Pharm Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩87,400.00 |
| 52 Week High | ₩120,800.00 |
| 52 Week Low | ₩60,500.00 |
| Beta | 0.59 |
| 1 Month Change | -1.69% |
| 3 Month Change | -8.67% |
| 1 Year Change | 37.85% |
| 3 Year Change | -18.85% |
| 5 Year Change | 194.28% |
| Change since IPO | 79.10% |
Recent News & Updates
Does ST PharmLtd (KOSDAQ:237690) Have A Healthy Balance Sheet?
Jan 21
Should You Be Adding ST PharmLtd (KOSDAQ:237690) To Your Watchlist Today?
Nov 22ST Pharm Co.,Ltd.'s (KOSDAQ:237690) Shares Climb 29% But Its Business Is Yet to Catch Up
Aug 30Recent updates
Does ST PharmLtd (KOSDAQ:237690) Have A Healthy Balance Sheet?
Jan 21Should You Be Adding ST PharmLtd (KOSDAQ:237690) To Your Watchlist Today?
Nov 22ST Pharm Co.,Ltd.'s (KOSDAQ:237690) Shares Climb 29% But Its Business Is Yet to Catch Up
Aug 30Is Now The Time To Put ST PharmLtd (KOSDAQ:237690) On Your Watchlist?
Aug 17Is ST Pharm Co.,Ltd. (KOSDAQ:237690) Trading At A 41% Discount?
May 09Why ST PharmLtd's (KOSDAQ:237690) Earnings Are Better Than They Seem
Mar 22ST Pharm Co.,Ltd. (KOSDAQ:237690) Stock Rockets 54% As Investors Are Less Pessimistic Than Expected
Mar 18Investors Who Bought ST PharmLtd (KOSDAQ:237690) Shares A Year Ago Are Now Up 221%
Mar 16Calculating The Fair Value Of ST Pharm Co.,Ltd. (KOSDAQ:237690)
Jan 22What Type Of Shareholders Own The Most Number of ST Pharm Co.,Ltd. (KOSDAQ:237690) Shares?
Dec 23Health Check: How Prudently Does ST PharmLtd (KOSDAQ:237690) Use Debt?
Nov 26
Shareholder Returns
| A237690 | KR Pharmaceuticals | KR Market | |
|---|---|---|---|
| 7D | 0% | -0.6% | -0.4% |
| 1Y | 37.9% | 10.7% | -0.7% |
Return vs Industry: A237690 exceeded the KR Pharmaceuticals industry which returned 10.7% over the past year.
Return vs Market: A237690 exceeded the KR Market which returned -0.7% over the past year.
Price Volatility
| A237690 volatility | |
|---|---|
| A237690 Average Weekly Movement | 7.5% |
| Pharmaceuticals Industry Average Movement | 5.6% |
| Market Average Movement | 6.7% |
| 10% most volatile stocks in KR Market | 12.9% |
| 10% least volatile stocks in KR Market | 3.4% |
Stable Share Price: A237690 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A237690's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1983 | 655 | Mooje Sung | www.stpharm.co.kr |
ST Pharm Co.,Ltd., provides custom manufacturing services for active pharmaceutical ingredient and intermediates in South Korea and internationally. The company offers small molecule and generics, an ingredient for treating viral infections; oligonucleotide based products, such as siRNA/microRNA, antisense, aptamer, decoys, and other novel oligos; monomer; and mRNA for vaccines and therapeutics. It also offers pre-clinical and bioanalytical R and D solutions.
ST Pharm Co.,Ltd. Fundamentals Summary
| A237690 fundamental statistics | |
|---|---|
| Market cap | ₩1.76t |
| Earnings (TTM) | ₩32.39b |
| Revenue (TTM) | ₩278.64b |
54.4x
P/E Ratio6.3x
P/S RatioIs A237690 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A237690 income statement (TTM) | |
|---|---|
| Revenue | ₩278.64b |
| Cost of Revenue | ₩184.60b |
| Gross Profit | ₩94.05b |
| Other Expenses | ₩61.66b |
| Earnings | ₩32.39b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.61k |
| Gross Margin | 33.75% |
| Net Profit Margin | 11.62% |
| Debt/Equity Ratio | 24.3% |
How did A237690 perform over the long term?
See historical performance and comparisonDividends
0.6%
Current Dividend Yield30%
Payout RatioDoes A237690 pay a reliable dividends?
See A237690 dividend history and benchmarks| ST PharmLtd dividend dates | |
|---|---|
| Ex Dividend Date | Dec 27 2024 |
| Dividend Pay Date | Apr 24 2025 |
| Days until Ex dividend | 35 days |
| Days until Dividend pay date | 83 days |
Does A237690 pay a reliable dividends?
See A237690 dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/30 02:02 |
| End of Day Share Price | 2025/01/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
ST Pharm Co.,Ltd. is covered by 20 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Heeyoung Lee | Daishin Securities Co. Ltd. |
| Yoonjin Lim | Daishin Securities Co. Ltd. |
| Jisoo Lee | DAOL Investment & Securities Co., Ltd. |